Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.

Trial Details

NCT ID
NCT05254327
Phase
PHASE2
Sponsor
University of Nebraska
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • BMX-001
Locations (sample)
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Patients with pathologically confirmed locally advanced rectal adenocarcinoma who will be receiving total neoadjuvant therapy regimen with curative…
  • AJCC stage II to III rectal adenocarcinoma that will require total neoadjuvant therapy.
  • Adult, age \> or equal to 18 years (for Nebraska, age of consent is ≥19 years old)
  • ECOG Performance Status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →